


FORM PTO-1390 (REV. 12-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				78104.037
INTERNATIONAL APPLICATION NO. PCT/GB00/03292		INTERNATIONAL FILING DATE 24 AUGUST 2000	U.S. APPLICATION NO. (If known, see 37 CFR 1.5 10/049783	
TITLE OF INVENTION STIMULATION OF SPERM FUNCTION		PRIORITY DATE CLAIMED 26 AUGUST 1999		
APPLICANT(S) FOR DO/EO/US FRASER, Lynn Repsis				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <ul style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <ul style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <ul style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (Unsigned)</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>				
Items 11 to 20 below concern document(s) or information included:				
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input type="checkbox"/> Other items or information:</p>				

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO PCT/GB00/03292		ATTORNEY'S DOCKET NUMBER 78104.037
21. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY		
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):				
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....		\$1040.00		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO		\$890.00		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO		\$740.00		
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)		\$710.00		
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)		\$100.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 890.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 130.00		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	55 - 20 =	35	x \$18.00	\$ 630.00
Independent claims	5 - 3 =	2	x \$84.00	\$ 168.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$280.00 \$ -0-		
TOTAL OF ABOVE CALCULATIONS =		\$ 1,318.00		
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		+ \$ -0-		
SUBTOTAL =		\$ 1,318.00		
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$ -0-		
TOTAL NATIONAL FEE =		\$ 1,318.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+ \$ -0-		
TOTAL FEES ENCLOSED =		\$ 1,318.00		
		Amount to be refunded:	\$	
		charged:	\$	
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1,318.00</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>18-2055</u> A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>				
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO:</p> <p>Joseph T. Leone DeWitt Ross & Stevens S.C. 8000 Excelsior Drive. Madison, WI 53717-1914 Phone: (608) 831-2100 Fax: (608) 831-2106</p>				
<p> SIGNATURE Joseph T. Leone</p> <p>NAME _____</p> <p>37,170 REGISTRATION NUMBER</p>				

1000 10/049783
JC13 Rec'd PCT/PTC 15 FEB 2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PRELIMINARY AMENDMENT (37 CFR §1.121/MPEP 714.09)

Box: PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

To the Commissioner:

Prior to calculation of the filing fee and examination of the above-referenced application on the merits, please amend the claims to read as follows:

IN THE CLAIMS

Please amend Claim 1 to read as follows:

1. [AMENDED] A medication for increasing capacitation of mammalian sperm, the medication comprising a combination of two or more agents selected from the group consisting of calcitonin, angiotensin II, and a modulator of adenosine receptor activity.

Please cancel Claims 2-33, without prejudice on the merits to further prosecution of these claims in one or more continuing applications.

Please add new Claims 34-87, as follows:

I certify that this correspondence is being deposited with the United States Postal Service as Express Mail - Post Office to Addressee, in an envelope addressed to: Box: PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.

EL 847502378KS 15 February 2002
Express Mail Label No. Date of Deposit

34. [NEW] The medication of Claim 1, wherein the modulator of adenosine receptor activity is selected from the group consisting of fertilization promoting peptide, adenosine, and a specific adenosine receptor agonist.

35. [NEW] The medication of Claim 1, wherein the modulator of adenosine receptor activity is selected from the group consisting of fertilization promoting peptide, adenosine, and a combination of fertilization promoting peptide and adenosine.

36. [NEW] The medication of Claim 1, comprising a combination of calcitonin and fertilization promoting peptide.

37. [NEW] The medication of Claim 1, comprising a combination of calcitonin, angiotensin II and fertilization promoting peptide.

38. [NEW] The medication of Claim 1, comprising a combination of calcitonin, angiotensin II, fertilization promoting peptide, and adenosine.

39. [NEW] The medication of Claim 1, wherein the calcitonin is selected from the group consisting of salmon calcitonin, porcine calcitonin, and human calcitonin.

40. [NEW] The medication of Claim 1, further comprising a pharmaceutically-suitable carrier.

41. [NEW] A composition of matter treating infertility in humans, the composition comprising a combination of two or more agents selected from the group consisting of calcitonin, angiotensin II, and a modulator of adenosine receptor activity.

42. [NEW] The composition of Claim 41, wherein the modulator of adenosine receptor activity is selected from the group consisting of fertilization promoting peptide, adenosine, and a specific adenosine receptor agonist.

43. [NEW] The composition of Claim 41, wherein the modulator of adenosine receptor activity is selected from the group consisting of fertilization promoting peptide, adenosine, and a combination of fertilization promoting peptide and adenosine.

44. [NEW] The composition of Claim 41, comprising a combination of calcitonin and fertilization promoting peptide.

45. [NEW] The composition of Claim 41, comprising a combination of calcitonin and adenosine.

46. [NEW] The composition of Claim 41, comprising a combination of calcitonin and angiotensin II.

47. [NEW] The composition of Claim 41, comprising a combination of fertilization promoting peptide and adenosine.

48. [NEW] The composition of Claim 41, comprising a combination of fertilization promoting peptide and angiotensin II.

49. [NEW] The composition of Claim 41, comprising a combination of angiotensin II and adenosine.

50. [NEW] The composition of Claim 41, comprising a combination of calcitonin, angiotensin II and fertilization promoting peptide.

51. [NEW] The composition of Claim 41, comprising a combination of calcitonin, angiotensin II, fertilization promoting peptide, and adenosine.

52. **[NEW]** The composition of Claim 41, further comprising a pharmaceutically-suitable carrier.
53. **[NEW]** The composition of Claim 52, wherein the carrier is suitable for topical application.
54. **[NEW]** The composition of Claim 53, comprising from about 100 nM to about 100 μ M fertilization promoting peptide, from about 5 ng/ml to about 5 μ g/ml salmon calcitonin, and from about 1 nM to about 1 μ M angiotensin II.
55. **[NEW]** The composition of Claim 53, comprising from about 10 μ M to about 10 mM adenosine, from about 5 ng/ml to about 5 μ g/ml salmon calcitonin, and from about 1 nM to about 1 μ M angiotensin II.
56. **[NEW]** The composition of Claim 53, comprising from about 100 nM to about 100 μ M fertilization promoting peptide, from about 200 ng/ml to about 200 μ g/ml human calcitonin, and from about 1 nM to about 1 μ M angiotensin II.
57. **[NEW]** The composition of Claim 53, comprising from about 10 μ M to about 10 mM adenosine, from about 200 ng/ml to about 200 μ g/ml human calcitonin, and from about 1 nM to about 1 μ M angiotensin II.
58. **[NEW]** A composition of matter comprising human sperm admixed with a combination of two or more agents selected from the group consisting of calcitonin, angiotensin II, and a modulator of adenosine receptor activity.
59. **[NEW]** The composition of Claim 58, wherein the modulator of adenosine receptor activity is selected from the group consisting of fertilization promoting peptide, adenosine, and a specific adenosine receptor agonist.

60. [NEW] The composition of Claim 58, wherein the modulator of adenosine receptor activity is selected from the group consisting of fertilization promoting peptide, adenosine, and a combination of fertilization promoting peptide and adenosine.

61. [NEW] The composition of Claim 58, comprising a combination of calcitonin and fertilization promoting peptide.

62. [NEW] The composition of Claim 58, comprising a combination of calcitonin, angiotensin II and fertilization promoting peptide.

63. [NEW] The composition of Claim 58, comprising a combination of calcitonin, angiotensin II, fertilization promoting peptide, and adenosine.

64. [NEW] The composition of Claim 58, further comprising a pharmaceutically-suitable carrier.

65. [NEW] The composition of Claim 58, comprising from about 25 nM to about 500 nM fertilization promoting peptide.

66. [NEW] The composition of Claim 58, comprising from about 12.5 nM to about 500 nM fertilization promoting peptide.

67. [NEW] The composition of Claim 58, comprising from about 0.5 μ M to about 100 μ M adenosine.

68. [NEW] The composition of Claim 58, wherein the calcitonin is selected from the group consisting of salmon calcitonin at a concentration of from about 0.5 ng/ml to about 150 ng/ml and human calcitonin at a concentration of from about 2 ng/ml to about 1,000 ng/ml.

69. [NEW] The composition of Claim 58, comprising from about 0.1 nM to about 100 nM angiotensin II.

70. [NEW] The composition of Claim 58, wherein the composition is frozen.

71. [NEW] The composition of Claim 58, wherein the composition has been frozen and thawed.

72. [NEW] A method of promoting fertility in mammals, the method comprising administering to a mammal, simultaneously, sequentially, or separately, a fertility-enhancing amount of two or more agents selected from the group consisting of calcitonin, angiotensin II, and a modulator of adenosine receptor activity.

73. [NEW] The method of Claim 72, wherein the modulator of adenosine receptor activity is selected from the group consisting of fertilization promoting peptide, adenosine, and a specific adenosine receptor agonist.

74. [NEW] The method of Claim 72, wherein the modulator of adenosine receptor activity is selected from the group consisting of fertilization promoting peptide, adenosine, and a combination of fertilization promoting peptide and adenosine.

75. [NEW] The method of Claim 72, wherein calcitonin and fertilization promoting peptide are administered.

76. [NEW] The method of Claim 72, wherein calcitonin, angiotensin II and fertilization promoting peptide are administered.

77. [NEW] The method of Claim 72, wherein calcitonin, angiotensin II, fertilization promoting peptide, and adenosine are administered.

78. [NEW] The method of Claim 72, wherein a calcitonin selected from the group consisting of salmon calcitonin, porcine calcitonin, and human calcitonin is administered.

79. [NEW] A method of *in vitro* fertilization or artificial insemination, the method comprising adding to mammalian sperm, simultaneously, sequentially, or separately, a capacity-enhancing amount of two or more agents selected from the group consisting of calcitonin, angiotensin II, and a modulator of adenosine receptor activity.

80. [NEW] The method of Claim 79, wherein the modulator of adenosine receptor activity is selected from the group consisting of fertilization promoting peptide, adenosine, and a specific adenosine receptor agonist.

81. [NEW] The method of Claim 79, wherein the modulator of adenosine receptor activity is selected from the group consisting of fertilization promoting peptide, adenosine, and a combination of fertilization promoting peptide and adenosine.

82. [NEW] The method of Claim 79, wherein calcitonin and fertilization promoting peptide are added.

83. [NEW] The method of Claim 79, wherein calcitonin, angiotensin II and fertilization promoting peptide are added.

84. [NEW] The method of Claim 79, wherein calcitonin, angiotensin II, fertilization promoting peptide, and adenosine are added.

85. [NEW] The method of Claim 79, wherein a calcitonin selected from the group consisting of salmon calcitonin, porcine calcitonin, and human calcitonin is added.

86. [NEW] A method of stimulating capacitation of mammalian sperm, the method comprising

adding angiotensin II to sperm, administering angiotensin II to a male mammalian subject in need thereof, or delivering angiotensin II to a reproductive tract of a female mammalian subject to be inseminated.

87. [NEW] The method of Claim 86, wherein the angiotensin II is administered in combination with a pharmaceutically-suitable carrier and the angiotensin II is present in an amount of from about 0.5 nM to about 100 nM.


REMARKS

Claim 1 is amended herein. Claims 2-33 have been canceled. Claims 34-87 are newly added herein. All of the newly added claims find explicit support from Claims 1-33 as presented in the priority PCT application. No new matter is added.

Applicants submit that the application is now in condition for examination on the merits. Early notification of such action is earnestly solicited.

If any questions regarding the application arise, please contact the undersigned attorney. Telephone calls related to this application are welcomed and encouraged. The Commissioner is authorized to charge any fees or credit any overpayments relating to this application to deposit account number 18-2055.

For the Applicant,


Joseph T. Leone, Reg. No. 37,170
DEWITT ROSS & STEVENS S.C.
Firststar Financial Centre
8000 Excelsior Drive, Suite 401
Madison, Wisconsin 53717-1914
Telephone: (608) 831-2100
Facsimile: (608) 831-2106

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): **FRASER, Lynn Repsis**

Atty. Docket: **78104.037**

Title: **STIMULATION OF SPERM FUNCTION**

"MARKED UP" CLAIMS AS AMENDED, 37 CFR §1.121(c)(1)(ii)

1. **[AMENDED]** A [combined] medication for increasing [the] capacitation of mammalian sperm, the medication comprising a combination of two or more agents [each of which is] selected from the [groups] group consisting of [(1)] calcitonin, [(2)] angiotensin II, and [(3)] a modulator of adenosine receptor activity.

STIMULATION OF SPERM FUNCTION

This invention relates to the treatment of mammalian sperm to stimulate sperm function.

5 Although morphologically complete and capable of vigorous motility when they leave the male reproductive tract, mammalian sperm are not immediately able to fertilize oocytes. The acquisition of the capacity to fertilize an oocyte is termed capacitation. Once capacitated, sperm can undergo the acrosome reaction, a prerequisite for penetration of the zona pellucida and fusion with the oocyte plasma membrane. A defect in this mechanism results in a condition of infertility. At present 10 there is no real treatment for this problem.

Throughout the following description reference is made to various publications in the literature; a full reference list of these is given at the end of this specification.

15 Fertilization promoting peptide (FPP) has been shown to stimulate fertilizing ability in both mouse sperm (Green et al, 1994) and human sperm (Green et al, 1996a). FPP is a tripeptide (pGlu-Glu-ProNH₂) that has been detected in the prostate gland, seminal plasma and anterior pituitary of several mammals. Although no specific function has been ascribed to FPP of pituitary origin, evidence is accumulating that FPP 20 may play an important role in regulating sperm function both in vitro and in vivo. FPP elicits biphasic responses in mammalian sperm, stimulating capacitation in uncapacitated sperm (determined by using chlortetracycline fluorescence analysis and in vitro fertilization) and then inhibiting spontaneous acrosome reactions in capacitated sperm. Sperm that have spontaneously acrosome-reacted are not able to fertilize, so both responses to FPP are important.

25 FPP acts by binding to its receptor (TCP11). Adenosine (also found in seminal plasma), when bound to its own receptors, can stimulate the same responses as FPP. Furthermore, using FPP plus adenosine, whether at high, stimulatory concentrations or low concentrations at which neither compound is stimulatory, stimulated capacitation more than either used singly. This suggested that FPP and adenosine act on the same 30 signal transduction pathway (Green et al, 1996b). More recent investigations have revealed that both have a common component in the pathway, namely adenosine

receptors, the FPP receptor, TCP11, appears to interact with adenosine receptors in order to elicit a response. The responses appear to be mediated via G proteins and the adenylyl cyclase/cAMP signal transduction pathway. Stimulatory responses in uncapacitated cells involve stimulatory adenosine receptors and G proteins containing 5 $\text{G}\alpha_s$ subunits, resulting in increased cAMP production. Inhibitory responses in capacitated cells involve inhibitory adenosine receptors and G proteins with $\text{G}\alpha_i$ subunits, resulting in reduced cAMP production (Fraser & Adeoya-Osiguwa, 1999). Agonists specific for stimulatory adenosine receptors can mimic the effects of FPP and adenosine in uncapacitated cells, while agonists specific for inhibitory adenosine 10 receptors mimic the effects of FPP and adenosine in capacitated cells. In spite of these properties, neither FPP nor adenosine has been utilised to solve the problem with which the present invention is concerned.

Angiotensin II is an 8 amino acid hormone whose chief function is the regulation of cardiovascular and electrolyte homeostasis. The addition of angiotensin II 15 to human sperm suspensions has been observed to stimulate sperm motility, suggesting that sperm have angiotensin II receptors and that angiotensin II may play a role in regulating sperm function (Vinson et al, 1997). This development is the subject of International patent application WO 95/32725. However, the problem to be overcome is one of stimulating sperm capacitation as distinct from sperm motility.

20 We have now found that, as well as stimulating sperm motility, angiotensin II stimulates the capacitation of mammalian sperm. The present invention therefore comprises the use of angiotensin II for this purpose.

The term 'angiotensin II' as used herein includes precursors and derivatives 25 which have similar activities in vivo and in vitro. Synthetic equivalents may also be used. Production of angiotensin II involves firstly conversion of angiotensinogen to angiotensin I by renin and then conversion of angiotensin I to angiotensin II by angiotensin converting enzyme. This renin-angiotensin system is usually thought of in terms of the systemic blood-borne system, but studies during the past 2 decades have 30 revealed the presence of elements of this system in the reproductive tract. Prorenin, the precursor of renin, and angiotensin II have both been identified in human seminal plasma.

Calcitonin is a 32-amino acid hypocalcemic hormone whose chief function is the regulation of Ca^{2+} fluxes and metabolism. There are three main phylogenetic classes of calcitonin, teleost/avian, artiodactyl and rat/human (Pozvek et al, 1997) Teleost/avian calcitonin is the most potent, with salmon calcitonin being widely used to treat human metabolic bone disorders. The term 'calcitonin' as used herein refers to calcitonin of any species including calcitonin of salmon, eel, chicken, porcine, bovine, rat and human origin, as well as precursors and derivatives which have similar activities in vivo and in vitro. Synthetic equivalents may also be used. In the early 1980s Calcitonin was identified in human seminal plasma, but negative conclusions were reached as to its effect on sperm. The first indication of a positive effect of calcitonin on sperm capacitation has been disclosed in our co-pending application WO 00/32224.

In accordance with the present invention, we have also found that combinations of two or more of the hormones referred to above and other substances specified hereinafter, produce an augmentation of capacitation which may be used to considerable advantage in therapy for infertility.

The present invention comprises a combined medication for stimulating the capacitation of mammalian sperm, comprising two or more agents each selected from one of the groups consisting of (1) calcitonin, (2) angiotensin II, and (3) a modulator of adenosine receptor activity.

The modulator of adenosine receptor activity may be selected from FPP, adenosine, and adenosine receptor agonists. For the purposes of this invention, the term 'FPP' used herein also includes precursors, related peptides such as thyrotrophin releasing hormone (TRH) and derivatives which have similar activities in vivo and in vitro.

The substances specified above, when used in combinations of any two or more, act upon mammalian sperm to stimulate sperm function significantly more than any one hormone used singly. This augmentation of the stimulatory effect can be obtained not only when using high concentrations of the hormones but also with low concentrations at which the hormones are non-stimulatory when used individually. The reason for this augmentation is not at present fully understood, but it does suggest that the different hormones are acting in some way on the same signal transduction pathway. Since it has not been found possible to increase the stimulatory effect of any one of these individual

agents simply by increasing the concentration above a certain level, the therapeutic benefit of such combinations is unexpected and highly advantageous for the treatment of fertility problems. Because these hormones act through separate receptors, defects in one or other of these, varying in individual patients, may be the cause of subfertility. 5 Combination therapy therefore offers a more effective way of dealing with such problems

The amounts of these agents which are effective to stimulate capacitation will depend on the extent to which sperm to be treated are initially deficient. This may be determined by assay as indicated in WO 00/3224. See below for further details.

10 The invention will now be further described with reference to the accompanying drawings of which:

Figure 1 shows the stimulatory effect of Angiotensin II at both 1 and 10 nM on mouse sperm,

15 Figure 2 shows the effect of calcitonin and angiotensin II used in combinations of both high and low concentrations with uncapacitated mouse sperm,

Figure 3 shows the effect of low concentrations of calcitonin and angiotensin II, used in combination with a low concentration of FPP none of which give a significant response when used individually,

20 Figure 4 shows the effect of high concentrations of FPP, calcitonin and angiotensin II used in combination, and

Figure 5 shows that the inhibition by FPP and calcitonin of spontaneous acrosome loss uncapacitated mouse sperm is abolished by pertussis toxin. Angiotensin II does not interfere with this inhibition when used in combination with FPP and calcitonin.

25

DEMONSTRATION OF A STIMULATORY EFFECT USING ANGIOTENSIN II

Sperm suspension preparation for chlortetracycline analysis

The contents of cauda epididymides (3-4 cauda per ml of medium) from mature TO male mice (Harlan Olac, Bicester, U.K.) were released into 2 ml modified Tyrode's 30 medium (Fraser, 1993) in 30 mm sterile culture dishes and allowed to disperse for 5 min. Suspensions were then filtered through short columns of Sephadex G-25 (medium grade; Pharmacia, Uppsala, Sweden) to remove non-motile cells, aliquotted out to

different treatment groups and treated with nothing (control) or with the hormone of choice.

Human angiotensin II was used at final concentrations of 1 and 10 nM; FPP, used at a final concentration of 100 nM, served as a positive control. These short term incubations were carried out in 0.5 ml plastic microcentrifuge tubes at 37° C in an atmosphere of 5% CO₂, 5% O₂, 90% N₂. Following incubation, an aliquot of each treated suspension was analysed using CTC to determine whether any effects on capacitation and hence acquisition of fertilizing ability could be observed. Three replicate experiments were carried out (n=3).

In all experiments, a drop of each suspension was examined briefly for subjective motility evaluation. None of the experimental treatments had a deleterious effect on motility; judged subjectively, they all promoted more vigorous motility than that observed in untreated control samples.

Chlortetracycline fluorescence analysis

Chlortetracycline (CTC) fluorescence analysis was carried out as described by Green et al (1994). Assessments were made on an Olympus BX40 microscope equipped with phase contrast and BX-FLA epifluorescence optics using the wide blue-violet excitation cube (U-MWBV). The excitation beam passed through a 400-440 nm band pass filter and CTC fluorescence was observed through a DM 455 dichroic mirror. In each sample, at least 100 sperm were classified as expressing one of three patterns: F, with fluorescence over the entire head, a pattern characteristic of uncapacitated (non-fertilizing), acrosome-intact sperm; B, with a fluorescence-free band in the postacrosomal region, a pattern characteristic of capacitated (potentially fertilizing), acrosome-intact sperm; AR, with dull or absent fluorescence over the whole head, a pattern characteristic of acrosome-reacted (non-fertilizing) sperm.

Sperm preparation for in vitro fertilization

The contents of the cauda epididymides from 2 mature TO male mice were released into 2 ml modified Tyrode's medium in 30 mm sterile culture dishes and allowed to disperse for 5 min. Suspensions were then divided into 3 treatment groups, each in a 30 mm sterile dish, and treated with nothing (Control) or with hormone. Angiotensin II was used at a final concentration of 10 nM, FPP, used at 100 nM, again served as a positive control. Each suspension was overlaid with autoclaved liquid

paraffin and incubated for 40 min at 37° C in an atmosphere of 5% O₂, 5% CO₂, 90% N₂

In vitro fertilization analysis

Mature female TO mice were induced to superovulate by intraperitoneal injections of 7.5 IU equine chorionic gonadotrophin and approximately 50 hr later with 5 IU human chorionic gonadotrophin (hCG). Approximately 15 hr post-hCG, oviducts were removed and cumulus masses containing the oocytes were released into medium covered with liquid paraffin. Preincubated sperm suspensions were diluted ~10 fold into medium of the same composition used for initial incubation (i.e., without or with 10 hormone); 400 µl of diluted suspension were transferred to culture dishes, covered with liquid paraffin and oocytes were added. After 65 min co-incubation, oocytes were transferred to small droplets of control medium and at 75 min fixed with buffered formalin (4% formaldehyde in phosphate buffered saline).

Oocytes were stained with 0.75% aceto-orcein, mounted and assessed (Fraser, 15 1993). They were considered to be fertilized if they had resumed the second meiotic division and contained a decondensing sperm head.

Results

Epididymal mouse sperm treated with angiotensin II (AII) at both 1 and 10 nM capacitated at a significantly faster rate (**P<0.01) compared with untreated control 20 sperm (Fig. 1). This was evidenced by a significantly higher proportion of B pattern cells (characteristic of capacitated, potentially fertilizing cells) and a corresponding significantly lower proportion of F pattern cells (characteristic of uncapacitated, non-fertilizing cells). It was also observed that hormone-treated cells exhibited more active motility than untreated controls. The in vitro fertilization experiments demonstrated 25 that significantly more fertilized oocytes (P<0.025) were obtained with angiotensin II-treated sperm (96/174 = 55.2% oocytes fertilized) and FPP-treated sperm (81/142 = 57.0% oocytes fertilized) than with the untreated control sperm (25/128 = 19.5% oocytes fertilized).

DEMONSTRATION OF A STIMULATORY EFFECT USING COMBINATIONS OF HORMONES

Calcitonin, angiotensin II and FPP each stimulate capacitation to about the same extent (CTC analysis) when used singly. Once a significant response has been obtained, increasing the dose of an individual hormone does not increase the response markedly, e.g., 1 nM and 10 nM angiotensin II (Fig 1) elicited very similar responses, as did 100 nM and 250 nM FPP (Green et al, 1994). However, we have now demonstrated that when these hormones are used in various combinations of 2 or all 3, an augmented response is obtained. In some experiments a 'high' concentration of hormone was used (5 ng/ml salmon calcitonin, 1 nM angiotensin II; 100 nM FPP) and in others, a 'low', non-stimulatory concentration was used (0.5 ng/ml calcitonin, 0.1 nM angiotensin II; 12.5 nM FPP).

When the combination of 5 ng/ml calcitonin + 1 nM angiotensin II (high concentrations; HiCT+AII) was evaluated, the stimulatory response observed using CTC analysis was greater than that seen when either one was used individually (**P<0.025, ***P<0.01 compared with untreated controls; Fig. 2). Although neither 0.5 ng/ml calcitonin nor 0.1 nM angiotensin II (low concentrations; LoCT, LoAII) caused any detectable response in treated mouse sperm suspensions when used individually, the two low doses used in combination (LoCT+AII) produced a significant stimulatory response (**P<0.025 compared with the untreated controls and low dose treatments; Fig. 2). However, this result is not to be explained in terms of an additive effect of two active components since Fig. 2 shows that the components used individually at low concentrations gave no improvement in capacitation over the control, which received no treatment. These latter results suggest that the two hormones, although known to act via their own separate receptors, may be acting on the same pathway. This hypothesis would be consistent with both the augmented response to combined high doses and the significant response to the combined low doses which were non-stimulatory when used singly.

When these two hormones were used in combination with FPP, similar responses were observed. Using low, non-stimulatory concentrations, the combinations of both 12.5 nM FPP + 0.5 ng/ml calcitonin (LoF+CT) and 12.5 nM FPP + 0.1 nM angiotensin II (LoF+AII) produced a similar and significant stimulatory response

(**P<0.025 compared with untreated controls, Fig. 3). When 12.5 nM FPP + 0.5 ng/ml calcitonin + 0.1 nM angiotensin II was used (LoF+CT+AII), an even greater stimulation was obtained (**P<0.01 compared with untreated controls; Fig. 3); the magnitude of this response was similar to that obtained with 100 nM FPP (HiF). Finally, when high concentrations of all three hormones (100 nM FPP, 5 ng/ml calcitonin, 1 nM angiotensin II; HiFPP+CT+AII) were used simultaneously, a very marked stimulatory response was obtained, significantly higher (!=P<0.05) than that obtained with 100 nM FPP (HiFPP) and in untreated controls (**P<0.001, Fig. 4)

Because FPP has been shown to modulate the adenylyl cyclase/cAMP signal transduction pathway, these results suggested that calcitonin and angiotensin II may somehow also modulate this same pathway. Very recent data shown below confirm that calcitonin can significantly stimulate cAMP production in uncapacitated sperm

Treatment	pmol cAMP/10 ⁷ cells (mean ± SEM)
None (control)	21.96 ± 7.98
FPP (100 nM)	28.56 ± 9.25 *
Calcitonin (salmon, 5 ng/ml)	30.58 ± 10.80 *

*P<0.05; significantly higher than untreated control

15

It should be reiterated that adenosine has been shown to utilise the same pathway as FPP; this involves adenosine receptors, with different receptor populations participating in responses to both FPP and adenosine in uncapacitated and capacitated sperm (Fraser & Adeoya-Osiguwa, 1999). New data shown below demonstrate that the 20 combination of low FPP and low adenosine, neither of which is effective when used individually, significantly stimulates cAMP production, the amount of cAMP produced being very similar to that produced in response to either high FPP or high adenosine

Treatment	pmol cAMP/10 ⁷ cells (mean \pm SEM)	
	2 min	4 min
None (control)	13.70 \pm 1.12	12.74 \pm 0.66
Hi FPP (100 nM)	18.87 \pm 1.52 *	15.73 \pm 1.71 *
Hi adenosine (10 μ M)	18.70 \pm 1.67 *	15.93 \pm 1.34 *
Lo FPP (12.5 nM) + Lo adenosine (1 μ M)	16.72 \pm 1.34 *	17.34 \pm 1.75 *

*P<0.05; significantly higher than in untreated control

Thus combinations of compounds acting on the cAMP pathway result in increased production of cAMP in uncapacitated cells. Therefore one preferred 5 combination is that of either FPP or adenosine, plus calcitonin and angiotensin II.

EFFECTS ON CAPACITATED SUSPENSIONS

FPP and adenosine have been shown to have a biphasic effect on mouse sperm, stimulating capacitation in uncapacitated sperm and then inhibiting the spontaneous 10 acrosome reaction in capacitated sperm. It is important to know what effect, if any, calcitonin and angiotensin II have on capacitated sperm since treated sperm will remain in the presence of hormones for several hours. If, for example, these hormones stimulated spontaneous acrosome reactions in capacitated cells, then the effectiveness 15 of the proposed treatment might be lessened since acrosome-reacted sperm are non-fertilizing. Therefore, the effects of calcitonin and angiotensin II used singly or in combination, including a combination of these hormones plus FPP, on capacitated sperm were investigated using CTC.

Sperm suspensions were prepared as described earlier for CTC analysis and 20 incubated for 90 min to allow capacitation. Suspensions were then filtered to remove non-motile cells and a sample was stained with CTC. The remaining suspension was aliquotted out to different treatment groups and treated with nothing or hormone, singly and in combination: 100 nM FPP; 5 ng/ml salmon calcitonin, 1 nM angiotensin II; calcitonin + angiotensin II; FPP + calcitonin + angiotensin II. After a further incubation 25 for 40 min (total of 130 min), sperm were prepared for CTC analysis. On the basis of a

preliminary experiment, which indicated that calcitonin had an effect while angiotensin II did not, two additional treatments were included: 100 nM FPP + 100 ng/ml pertussis toxin; 5 ng/ml calcitonin + 100 ng/ml pertussis toxin

Results (Fig. 5) indicated that both FPP (F) and calcitonin (CT) significantly inhibited the spontaneous acrosome reaction (**P<0.01 compared with untreated controls at 130 min), whereas angiotensin II (AII) did not. Therefore, although the results obtained with uncapacitated sperm suggest that these three hormones act on the same pathway, these results indicate that more than one mechanism of action is probably involved. The inclusion of pertussis toxin (PT) abolished the effects of FPP (F+PT) and calcitonin (CT+PT), suggesting that responses in capacitated sperm to these two hormones involve G proteins with inhibitory $G\alpha_{i/o}$ subunits. The fact that angiotensin II did not inhibit spontaneous acrosome reactions suggests that a different mechanism, one not involving inhibitory G proteins, is involved in responses to this hormone. Using a combination of calcitonin + angiotensin II (data not shown) or FPP + calcitonin + angiotensin II (F+CT+AII; Fig. 5) resulted in significant inhibition of spontaneous acrosome loss (**P<0.01 compared with untreated controls at 130 min). Therefore, the inability of angiotensin II to elicit a biphasic response did not interfere with responses to FPP and calcitonin, each of which does elicit a biphasic response. These results suggest that an extended exposure of sperm to a combination of these hormones would have no deleterious effect, but would instead result in a high proportion of potentially fertilizing sperm.

CLINICAL APPLICATIONS

Therapeutic

As one highly preferred combination, we propose the combined use of FPP or adenosine, calcitonin and angiotensin II both in vitro and in vivo. The fact that this combination of hormones both stimulates capacitation and then inhibits spontaneous acrosome reactions should maximize the number of potentially fertilizing sperm (capacitated, acrosome-intact) in the sample. Individual men may have sperm with defects in one or more of the receptor-mediated responses controlled by these

hormones. Use of a mixture of all the hormones increases the chances that sperm will respond to at least one or two of the hormones in the mixture.

Uses in vitro in infertility clinics

Procedures used in infertility clinics to prepare human sperm samples for either 5 in vitro fertilization or intrauterine insemination involve washing the sperm free of seminal plasma and hence of the hormones therein. A single hormone or a mixture containing all 3 hormones can be added to these prepared sperm samples prior to their use. Motile sperm should be selected by layering unwashed semen on top of discontinuous gradients of a dense material such as PureSperm prepared in a suitable 10 culture medium such as Earle's medium (e.g., 95, 70 and 50% PureSperm in Earle's), centrifuging for 5-10 min at 600 g and resuspending the pelleted cells to a concentration of 5×10^6 sperm/ml in fresh medium containing the combined hormones.

For some men, addition of angiotensin II to the prepared sperm suspensions to give a final concentration of 0.1 to 100 nM (preferably 0.5 to 100 nM) would be 15 recommended. For more general use, we recommend adding hormones to give final concentrations of FPP from 12.5 to 500 nM (preferably 25 to 500 nM) or adenosine from 0.5 to 100 μ M, salmon calcitonin from 0.5 to 150 ng/ml (preferably 2 to 150 ng/ml) or human calcitonin from 2 to 2000 ng/ml (preferably 20 to 1000 ng/ml), and angiotensin II from 0.1 to 100nM (preferably 0.5 to 100 nM) in the prepared 20 suspensions. We then recommend incubation of sperm suspensions in the presence of FPP/adenosine + calcitonin + angiotensin II for a minimum of 1-3 h at 37° C in an atmosphere of 5% CO₂, then mixing with oocytes if doing in vitro fertilization or insemination into the uterine cavity for intrauterine insemination.

In addition to being used for men with dysfunctional sperm, these procedures 25 could be used routinely in infertility clinics for all sperm suspensions used for IVF. The hormones should have a positive effect on most sperm samples and, by increasing the number of capacitated, potentially fertilizing sperm in each sample, lower numbers of sperm could be used for insemination in vitro. This should reduce the incidence of polyspermic fertilization (fertilization by 2 or more sperm), a desirable goal since 30 polyspermic embryos are abnormal and are never transferred

Semen samples used for donor insemination must be frozen and stored in quarantine for at least six months before use. Freezing and thawing sperm can cause damage, in some cases making it more likely that sperm will undergo the spontaneous acrosome reaction, this would impair the fertilizing ability. The ability of these 5 hormones, especially in combination, to inhibit spontaneous acrosome reactions might allow them to protect the sperm from such damage. All these hormones are found in seminal plasma and so would be present in samples being frozen. However, prior to freezing, semen is mixed with cryoprotectant which will reduce the concentration of hormones present. To protect the sperm from undergoing spontaneous acrosome 10 reactions as a result of freezing and thawing we recommend adding hormones either to fresh semen prior to freezing or to thawed semen immediately after thawing, prior to insemination. We recommend adding hormones to give final concentrations of added FPP from 12.5 nM to 1 μ M, or adenosine from 0.5 to 100 μ M, salmon calcitonin from 0.5 to 400 ng/ml, or human calcitonin from 2 to 1000 ng/ml, and angiotensin II from 0.1 15 to 100 nM in the semen.

Uses in vivo

In order to increase the concentration of these hormones available to sperm at the time they enter the female reproductive tract, one can use creams, jellies or pessaries containing a mixture of FPP or adenosine, calcitonin and angiotensin II. To ensure that 20 there is sufficient hormone to interact with ejaculated sperm, the concentration of hormones used should preferably be higher than that used for addition to prepared sperm in vitro. We recommend using preparations containing the following hormone concentrations: from 100 nM to 100 μ M FPP or 10 μ M to 10 mM adenosine, from 5 ng/ml to 5 μ g /ml of salmon calcitonin or from 200 ng/ml to 5 μ g/ml of human 25 calcitonin and from 1 nM to 1 μ M angiotensin II.

AGRICULTURAL APPLICATIONS

The present invention is applicable also to stimulating fertilizing ability of sperm in domestic animals. In many agriculturally important species (e.g., cattle, pigs, 30 sheep) artificial insemination using either fresh or frozen/thawed semen samples is used to establish pregnancies. This is particularly important in controlled breeding.

programmes where it is commercially advantageous for farmers to have specific genetically-determined traits introduced into their stock. Because FPP, adenosine, calcitonin and angiotensin II stimulate fertilizing ability in mouse sperm, a similar stimulatory effect on sperm from these various animals can be expected. In support of 5 this, a recent study has demonstrated that FPP and adenosine have a biphasic effect on boar sperm, stimulating capacitation and inhibiting spontaneous acrosome loss (Funahashi et al, 2000). Treating the sperm with these hormones is intended to improve pregnancy rates, especially when frozen/thawed semen is being used.

Mammalian sperm are frequently damaged by freezing and thawing and this 10 results in lower fertility. By improving the performance of the viable sperm, a mixture containing FPP or adenosine, calcitonin and angiotensin II added to the sperm preparation used for insemination should promote a higher pregnancy rate per estrus cycle, reducing the number of cycles required to ensure conception and hence reducing the overall cost of artificial insemination. At the same time, semen from animals with 15 highly desirable traits can be used to inseminate more females because fewer cycles would be needed to ensure conception in any one female. We recommend the addition of hormones to semen samples, either prior to freezing, or after thawing but prior to insemination to give final concentrations of added FPP from 12.5 nM to 1 μ M (preferably 50 nM to 1 μ M) or adenosine from 0.5 to 100 μ M, salmon calcitonin from 20 0.5 to 400 ng/ml (preferably 2 to 400 ng/ml) or porcine calcitonin from 2 to 1000 ng/ml (preferably 20 to 1000 ng/ml), and angiotensin II from 0.1 to 100 nM (preferably 0.5 to 100 nM).

For any mammalian application using angiotensin II alone we recommend a 25 composition containing from 1nM to 1 μ M angiotensin II or a sperm preparation containing from 0.5 to 100 nM angiotensin II.

REFERENCES

Fraser LR. (1993) In vitro capacitation and fertilization. *Methods Enzymol* 225, 239-253.

5 Fraser LR & Adeoya-Osiguwa SA. (1999) Modulation of adenylyl cyclase by FPP and adenosine involves stimulatory and inhibitory adenosine receptors and G proteins. *Mol Reprod Dev* 53: 459-471.

10 Funahashi H, Asano A, Fujiwara T, Nagai T, Niwa K & Fraser LR. (1999) Both fertilization promoting peptide and adenosine stimulate capacitation but inhibit spontaneous acrosome loss in ejaculated boar spermatozoa in vitro. *Mol. Reprod. Dev.* 55, 117-124.

15 Green CM, Cockle SM, Watson PF & Fraser LR. (1994) Stimulating effect of pyroglutamylglutamylprolineamide, a prostatic, TRH-related tripeptide, on mouse sperm capacitation and fertilizing ability in vitro. *Mol Reprod Dev* 38, 215-221.

Green CM, Cockle SM, Watson PF & Fraser LR. (1996a) Fertilization promoting peptide, a tripeptide similar to thyrotrophin-releasing hormone, stimulates the capacitation and fertilizing ability of human sperm in vitro. *Human Reprod* 11, 830-836.

20 Green CM, Cockle SM, Watson PF & Fraser LR. (1996b) A possible mechanism of action for fertilization promoting peptide, a TRH-related tripeptide that promotes capacitation and fertilizing ability in mammalian spermatozoa. *Mol. Reprod. Dev.* 45, 244-252.

25 Pozvek G, Hilton JM, Quiza M, Houssami S & Sexton PM. (1997) Structure/function relationships of calcitonin analogues as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system. *Mol Pharmacol* 51, 658-665.

Vinson GP, Saridogan E, Puddefoot JR & Djahanbakhch O. (1997) Tissue renin-angiotensin systems and reproduction. *Human Reprod* 12, 651-662.

CLAIMS

- 1 A combined medication for increasing the capacitation of mammalian sperm, comprising two or more agents each of which is selected from the groups consisting of (1) calcitonin, (2) angiotensin II, and (3) a modulator of adenosine receptor activity.
- 5
2. A combined medication according to claim 1, in which the modulator of adenosine receptor activity is fertilization promoting peptide (FPP) or adenosine or a specific adenosine receptor agonist.
- 10
3. A combined medication according to claim 1, in which the modulator of adenosine receptor activity is FPP, adenosine, or a mixture of FPP and adenosine (FPP/adenosine)
- 15
4. A combined medication according to claim 1, comprising the two agents consisting of calcitonin and FPP.
- 5
5. A combined medication according to claim 1, comprising calcitonin, FPP (or FPP/adenosine), and angiotensin II.
- 20
6. A composition for the treatment of infertility in humans, comprising a pharmaceutically acceptable carrier containing two or more of the agents specified in any of claims 1 to 5.
- 25
7. A composition for the treatment of infertility in humans, comprising a pharmaceutically acceptable carrier containing two or all of the hormones FPP (or FPP/adenosine), calcitonin and angiotensin II for topical application
- 30
8. A composition according to claim 7, being in the form of a cream or jelly or pessary.

9 A composition according to claim 7 or 8, containing from 100 nM to 100 μ M FPP or from 10 μ M to 10 mM adenosine, from 5 ng/ml to 5 μ g/ml salmon calcitonin or from 200 ng/ml to 200 μ g/ml of human calcitonin and from 1 nM to 1 μ M angiotensin II.

5

10 A sperm preparation for use in the treatment of infertility containing two or more agents each of which is selected from the groups consisting of (1) calcitonin, (2) angiotensin II, and (3) a modulator of adenosine receptor activity.

10 11. A sperm preparation according to claim 10, containing from 25 to 500 nM FPP or from 0.5 to 100 μ M adenosine.

12. A sperm preparation according to claim 10 or 11, containing from 2 to 150 ng/ml salmon calcitonin or from 20 to 1000 ng/ml g/ml human calcitonin.

15

13. A sperm preparation according to claim 10, 11, or 12, containing from 0.5 to 100 nM angiotensin II.

14. A sperm preparation for use in the treatment of infertility containing two or more 20 of the agents specified in claims 10 to 13, in the concentrations specified therein.

15. A sperm preparation according to claim 10, containing from 12.5 to 500 nM FPP or from 0.5 μ M to 100 μ M adenosine.

25 16. A sperm preparation according to claim 10 or 15, containing from 0.5 to 150 ng/ml salmon calcitonin or from 2 ng/ml to 1000 ng/ml of human calcitonin.

17. A sperm preparation according to claim 10, 15, or 16, containing from 0.1 to 100 nM angiotensin II.

30

18. A sperm preparation for use in the treatment of infertility containing two or more of the agents specified in claims 15 to 17 in the concentrations specified therein

19. A sperm preparation according to any of claims 10 to 18, for human clinical use

5

20. A sperm preparation according to claim 10, for agricultural use

21. A sperm preparation according to claim 20, containing concentrations of added FPP from 12.5 nM to 1 μ M (preferably 50 nM to 1 μ M) or adenosine from 0.5 to 100 μ M, salmon calcitonin from 0.5 to 400 ng/ml (preferably 2 to 400 ng/ml) or porcine calcitonin from 2 to 1000 ng/ml (preferably 20 to 1000 ng/ml), and angiotensin II from 0.1 to 100 nM (preferably 0.5 to 100 nM).

10

22. A frozen sperm preparation according to any of claims 10 to 21.

15

23. A thawed sperm preparation containing agents as specified in any of claims 10 to 21 added after thawing and prior to insemination.

20

24. The use of combined medication, composition, or sperm preparation according to any of the preceding claims, to promote fertilizing ability in mammalian sperm.

25. The use according to claim 24, in which the hormones are administered simultaneously, sequentially, or separately.

26

26. The use of human, porcine or salmon calcitonin, in conjunction with FPP/adenosine and human angiotensin II, to promote fertilizing ability in mammalian sperm.

30

27. A method of promoting fertility in mammals which comprises administering two or more of the agents specified in any of claims 1 to 5 administered simultaneously, sequentially, or separately.

28. A method of promoting fertility in mammals which comprises administering two or three of the hormones FPP/adenosine, calcitonin and angiotensin II to a mammal in need thereof.
- 5 29. A method of improving in vitro fertilization or artificial insemination which comprises adding two or more of the hormones calcitonin, FPP (or FPP/adenosine), and angiotensin II to sperm prior to use.
- 10 30. The use of angiotensin II in the preparation of a medicament for stimulating the capacitation of mammalian sperm.
31. A method of stimulating the capacitation of sperm which comprises adding angiotensin II to a sperm preparation or administering angiotensin II to a patient in need thereof or to the female reproductive tract.
- 15 32. A composition for stimulating the capacitation of sperm comprising angiotensin II.
33. A composition according to claim 32, containing from 1nM to 1 μ M angiotensin II, or being a sperm preparation containing from 0.5 to 100 nM angiotensin II.
- 20

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number
WO 01/13932 A2

(51) International Patent Classification⁷: **A61K 38/00**

(21) International Application Number: **PCT/GB00/03292**

(22) International Filing Date: 24 August 2000 (24.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9920262.4 26 August 1999 (26.08.1999) GB

(71) Applicant (for all designated States except US): KING'S COLLEGE LONDON [GB/GB]; The Strand, London WC2R 2LS (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): FRASER, Lynn, Repsis [GB/GB]; 7 The Highlands, Rickmansworth, Herts. WD3 2EW (GB).

(74) Agent: TOLLETT, Ian; Williams, Powell & Associates, 4 St. Paul's Churchyard, London EC4M 8AY (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STIMULATION OF SPERM FUNCTION

WO 01/13932 A2

(57) **Abstract:** A combined medicament for increasing the capacitation of mammalian sperm is described, comprising two or more agents each of which is selected from the groups consisting of (1) calcitonin, (2) angiotensin II, and (3) a modulator of adenosine receptor activity, which may be fertilization promoting peptide (FPP) or adenosine or a specific adenosine receptor agonist. A preferred combination is calcitonin, FPP (or FPP/adenosine), and angiotensin II. The agents may be formulated as (1) a cream, jelly or pessary containing from 100 nM to 100 μ M FPP or from 10 μ M to 10 mM adenosine, from 5 ng/ml to 5 μ g/ml salmon calcitonin or from 200 ng/ml to 200 μ g/ml of human calcitonin and from 1 nM to 1 μ M angiotensin II, or (2) as a sperm preparation for use in the treatment of human infertility containing from 12.5 to 500 nM FPP or from 0.5 μ M to 100 μ M adenosine, from 0.5 to 150 ng/ml salmon calcitonin or from 2 ng/ml to 1000 ng/ml of human calcitonin, and containing from 0.1 to 100 nM angiotensin II. For agricultural use a sperm preparation may contain concentrations of added FPP from 12.5 nM to 1 μ M or adenosine from 0.5 to 100 μ M, salmon calcitonin from 0.5 to 400 ng/ml or porcine calcitonin from 2 to 1000 ng/ml, and angiotensin II from 0.1 to 100 nM. The use of angiotensin II alone for the preparation of a medicament for stimulating the capacitation of mammalian sperm is also described.

**Figure 1**




Figure 2

3/5




Figure 3

4/5




Figure 4

5/5




Figure 5

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

Each undersigned inventor hereby declare(s) that:

- My residence, post office address and citizenship are as stated below next to my name.
- I believe that I am, in conjunction with any joint inventor(s) named herein, the original and first inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled **STIMULATION OF SPERM FUNCTION**, the patent application for which was filed as PCT international application number PCT/GB00/03292 on 24 August 2000.
- I reviewed and understand the contents of the above-identified patent application, including the specification and claims, as amended by any amendments referred to above.
- I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability, as defined in Section 1.56 of Title 37, U.S. Code of Federal Regulations.
- I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or (f), or §365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below. I have also identified any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

<i>Application No.</i>	<i>Country</i>	<i>Day/Month/Year</i>	<i>Priority Claimed</i>
PCT/GB00/03292	PCT	24/August/2000	YES
GB 9920262.4	Great Britain	26/August/1999	YES

I APPOINT the following registered practitioner(s) to prosecute this application and to transact all related business in the U.S. Patent and Trademark Office: Joseph T. Leone (37,170), Craig A. Fieschko (39,668), Charles S. Sara (30,492).

Address all telephone calls to:

Joseph T. Leone

Telephone: (608) 828-0743

Facsimile: (608) 831-2106

Address all correspondence to:

Intellectual Property Department
DEWITT ROSS & STEVENS S.C.
Firstar Financial Centre
8000 Excelsior Drive Suite 401
Madison, WI 53717-1914

I DECLARE THAT all statements made herein of my own knowledge are true; all statements made on information and belief are believed to be true; that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001; and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Lynn R. Fraser
Signature

March 8 2002
Month Day Year

First or Sole Inventor: Lynn Repsis FRASER

Post Office Address: 7 The Highlands
Rickmansworth, Herts, WD3 7EW GBK
United Kingdom

Citizenship: Great Britain